Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up. - Wikidata - wikimedia - TriplyDB

Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up.

Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up.

http://www.wikidata.org/entity/Q39514544

about

Historical review of the causes of cancer Long-term efficacy and safety of human papillomavirus vaccination HPV catch-up vaccination of young women: a systematic review and meta-analysis.Human papillomavirus prevalence and type distribution among women attending routine gynecological examinations in Saudi Arabia.Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010.Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.The hallmarks of premalignant conditions: a molecular basis for cancer prevention Screening adolescents and young women Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs.Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.Clinical trials of human papillomavirus vaccines and beyond.Targeting CDKN3 in cervical cancer.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.The next steps in cervical screening.Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.Expression of p16INK4A in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines.Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.Reply to Ryser et al.Nordic Cancer Registries - an overview of their procedures and data comparability.Vaccination protects against invasive HPV-associated cancers.Prevention of HPV disease burden.Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix

P2860

Q26767036-14CF83A6-76EC-4A20-B10D-A673C0B78FE9 Q28081156-7873BD95-F9F1-43DE-B717-C98A2B6339BF Q34157209-967A2682-3635-489C-98E7-805CBA1B7A51 Q34746772-B0412DD0-31C6-4099-9001-8646A33C8537 Q35437586-888DFA71-2406-4EB1-ADDF-9307DCEDBFEB Q36418117-2DCE1EBB-2391-4BFC-819C-3E18664DF5CD Q36679858-FDAE6454-D3E2-4BC6-9793-7E218079B463 Q36903551-C6BBCC62-6720-4AEA-AA6A-EF15918E14F0 Q37467138-5EBA6015-7736-4724-B0C2-5082B0562857 Q37561432-29C32CAC-A223-402C-89CA-6B499337B43C Q38111962-2F7F78BE-9765-48BE-82B3-0B8669365822 Q38242742-D29079AF-F899-4C87-99DD-702A10DB4D6E Q38255277-D1F07E3B-5FEE-424C-848A-F13DD95B5C0A Q38380092-060AA5C8-A954-4142-AD19-63AE36E68C7D Q38618078-543CD1EF-A208-4A32-BCF6-8B0C7FFEDCEE Q40293794-B89948B0-8B09-44AE-BE99-0F9E18BA4B37 Q40593007-F4D998D7-2033-4422-93FD-40C6A3856C59 Q42236236-85D13137-80FA-4F3E-8060-30F0DB187D71 Q44701708-6D049586-9F4B-4F88-ABB8-7FDC85F626CD Q47332633-1E8DDB79-8B85-4B04-9203-EFD6C4D20125 Q48345981-957514D5-683A-492E-8268-ED669BDEF5E0 Q51811189-5ECD0318-2923-4666-A915-B5D61E8B48AC Q57932049-7EF9E760-E834-4B90-A5F6-2B01AD2FC081

P2860

Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up.

http://www.wikidata.org/entity/Q39514544

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Understanding long-term protec ...... ncer registry-based follow-up.

@en

Understanding long-term protec ...... ncer registry-based follow-up.

@nl

type

label

Understanding long-term protec ...... ncer registry-based follow-up.

@en

Understanding long-term protec ...... ncer registry-based follow-up.

@nl

prefLabel

Understanding long-term protec ...... ncer registry-based follow-up.

@en

Understanding long-term protec ...... ncer registry-based follow-up.

@nl

P1433

Q39514544-E6C93997-878C-444C-8FE5-BEDBBE7ABFFE

P1476

Q39514544-A6008689-D5C3-4E3C-9075-E43CFF0716C2

P2093

Q39514544-42C07C90-5686-46DE-AE06-7C74DDEE43A7

Q39514544-5AD12C44-6AA7-4E41-B7A3-EED239777B96

Q39514544-9F0A0B01-A1F4-4AFA-91B1-BEBAF3041E50

Q39514544-A44BC5C4-5433-4197-952C-2512F98A83CA

Q39514544-FF07A0FA-D8B6-4CFD-9477-69774A17AD81

P2860

Q39514544-1F8F38FC-0325-47BF-8A18-E1745B1A8687

Q39514544-2B1805F5-45CB-40D7-900E-352F2FE3A2E7

Q39514544-346C06DB-2002-432B-A226-2EF4B2E02DAC

Q39514544-3B41FD3F-42BC-4930-8445-BEB9A4C3D401

Q39514544-4F930B2D-0D0C-47CB-9038-BD74BD4F4D06

Q39514544-5B97BFC1-9185-4BA7-B758-4FCE56D1088F

Q39514544-752F2468-5A72-41EE-B8A5-0A3EBD4BBA11

Q39514544-78A8981B-4D45-403D-81B5-419C98623B56

Q39514544-8DA017A0-E928-46DD-AB9B-202FC0D8B66B

Q39514544-956BA115-E2AC-441A-B47C-9943920A2D80

P304

Q39514544-A9F079CD-5028-4B0F-86FE-4BF02C6E6E38

P31

Q39514544-1506CC6F-14D2-4CAC-B766-89AD7DA70199

P356

Q39514544-BB29D69E-1E87-46DD-A347-B8B336A661A9

P433

Q39514544-DA2ECD4C-0220-4A0D-AD80-8A2844BBE3AE

P478

Q39514544-B69B5017-A8F0-45DC-9B56-FC0E40861079

P50

Q39514544-7403A322-D43A-4717-825D-76EFBE500EAA

Q39514544-82BC2B44-F719-40A1-9DD0-D95B4EE91B44

Q39514544-949BF880-4E0F-41C8-BBEA-C9D61B0DC04A

Q39514544-DF2CED71-1985-46FA-8C4A-B37C120B1C8A

P577

Q39514544-037A92C8-9E32-4D43-A76D-A8B84CEFC196

P698

Q39514544-966346F5-934B-4341-A504-65FE4B7E4F80

P356

P1433

International Journal of Cancer

P1476

Understanding long-term protec ...... ncer registry-based follow-up.

@en

P2093

Heini Huhtala

http://www.w3.org/2001/XMLSchema#string

Kari Natunen

http://www.w3.org/2001/XMLSchema#string

Matti Lehtinen

http://www.w3.org/2001/XMLSchema#string

Muhammad Mohsin Rana

http://www.w3.org/2001/XMLSchema#string

Tiina Eriksson

http://www.w3.org/2001/XMLSchema#string

P2860

The causal relation between human papillomavirus and cervical cancer.

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

Epidemiologic classification of human papillomavirus types associated with cervical cancer

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas

Data quality and quality control of a population-based cancer registry. Experience in Finland.

CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples.

P304

2833-2838

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.27971

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P50

Tapio Luostarinen

P577

2012-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23180157

http://www.w3.org/2001/XMLSchema#string